Such drawbacks are why a pill to alleviate sickle-cell, if developed, could sweep CRISPR from the playing field. A pill ...
The association technique hasn’t always paid off—but starting in 2007 the gene searches hit pay dirt for sickle-cell. In one ...
Even then, patients won’t get the treatments if insurers and governments balk at paying. It’s a real risk. For instance, ...
What You Should Know: – Cardinal Health (NYSE: CAH) has announced a definitive agreement to acquire Integrated Oncology Network (ION),...
Read moreWhat’s new: It’s tricky to get robots to do things in environments they’ve never seen before. Typically, researchers need to...
Read moreElon Musk, the CEO of X and various other companies with the letter “X” in their names, is in regulators’...
Read moreCards Against Humanity sued SpaceX for allegedly trespassing on and damaging its property in Texas. The company behind the card...
Read more
© Tech News Hubb All rights reserved.
Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.
/cdn.vox-cdn.com/uploads/chorus_asset/file/25355895/STK022_ELON_MUSK_CVIRGINIA_C.jpg)